administering to the subject a cell expressing a TSP-2 comprising an amino acid sequence at least 95% identical to the sequence of SEQ ID NO:2, or a functional fragment thereof, capable of inhibiting endothelial cell migration.

55. (Amended) The method of claim 54, wherein the cell is a genetically engineered cell modified to cause the expression of the TSP-2 or the functional fragment thereof.

56. (Reiterated) The method of claim 55, wherein the cell has been genetically modified to introduce a regulatory sequence that causes or increases the expression of an endogenous TSP-2 gene.

57. (Amended) The method of claim 55, wherein the cell comprises an exogenous nucleic aid encoding the TSP-2 or the functional fragment thereof.

58. (Reiterated) The method of claim 55, wherein the cell is autologous.

59. (Reiterated) The method of claim 56, wherein the cell is autologous.

60. (Reiterated) The method of claim 57, wherein the cell is autologous.

61. (Reiterated) The method of claim 55, wherein the cell is allogeneic.

62. (Reiterated) The method of claim 56, wherein the cell is allogeneic.

63. (Reiterated) The method of claim 57, wherein the cell is allogeneic.

64. (Reiterated) The method of claim 55, wherein the cell is xenogeneic.

65. (Reiterated) The method of claim 56, wherein the cell is xenogeneic.

66. (Reiterated) The method of claim 57, wherein the cell is xenogeneic.

67. (Reiterated) The method of claim 56, wherein the promoter of the endogenous TSP-2 gene has been replaced by a promoter from another gene.

68. (Reiterated) The method of claim 54, 55, 56 or 57, wherein the cell is an epithelial cell.

69. (Reiterated) The method of claim 54, 55, 56 or 57, wherein the cell is selected from the group consisting of: a fibroblast, a keratinocyte, an endothelial cell, a glial cell, a neural cell, a lymphocyte, a bone marrow cell, and a muscle cell.

70. (Reiterated) The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 2 days.

71. (Reiterated) The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 10 days.

72. (Reiterated) The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 14 days.

73. (Reiterated) The method of claim 55, wherein the level of TSP-2 in the subject after administration is increased for at least 30 days.

74. (Reiterated) The method of claim 54, 55, 56 or 57, wherein the disorder is characterized by pre-cancerous, cancerous or neoplastic cells.

75. (Reiterated) The method of claim 74, wherein the disorder is selected from the group consisting of: melanoma, prostate cancer, breast cancer, colon cancer, and lung cancer.

76. (Reiterated) The method of claim 54, wherein the subject is a human.

77. (Reiterated) The method of claim 55, wherein the subject is a human.

78. (Reiterated) The method of claim 56, wherein the subject is a human.

79. (Reiterated) The method of claim 57, wherein the subject is a human.

80. (Reiterated) The method of claim 54, 55, 56 or 57, wherein the disorder is selected from the group consisting of: psoriasis, rheumatoid arthritis, multiple sclerosis, diabetic retinopathy, and restenosis after coronary angioplasty.

Add new claims 81- 85.

81. A method of treating a subject having a disorder characterized by unwanted cell proliferation, the method comprising:

identifying a subject having a disorder characterized by unwanted cell proliferation; and

administering to the subject a cell expressing a TSP-2 comprising an amino acid sequence encoded by a nucleotide sequence that hybridizes to the nucleotide sequence of SEQ ID NO:2 under the hybridization conditions of: hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C, or a functional fragment thereof, capable of inhibiting endothelial cell migration.

82. A method of treating a subject having a disorder characterized by unwanted cell proliferation, the method comprising:

identifying a subject having a disorder characterized by unwanted cell proliferation; and

administering to the subject a cell expressing TSP-2 (SEQ ID NO:2).

83. The method of claim 54, wherein the TSP-2 is at least 97% identical to the sequence of SEQ ID NO:2.

84. The method of claim 54, wherein the TSP-2 is at least 98% identical to the sequence of SEQ ID NO:2.

85. The method of claim 54, wherein the TSP-2 is at least 99% identical to the sequence of SEQ ID NO:2.

In the drawings:

Please substitute the enclosed 7 sheets of formal drawings for the corresponding drawings presently in the application.